Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Prometheus Biosciences (NASDAQ: RXDX) Reports PRA023 Candidate Achieved Positive Results in Both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Clinical Trials

Prometheus Biosciences, Inc. (NASDAQ: RXDX) is engaged as a clinical-stage biotechnology company, which is focused on the research, development and commercialization of novel therapeutics for the treatment of immune-mediated diseases. Shares of the biotech company are skyrocketing 175% through early trading on Wednesday, December 7, 2022. Over the past three months, Prometheus Biosciences has seen average daily volume of 597,160 shares. However, volume of 6.14 million shares or dollar volume of around $610.56 million, has already exchanged hands through early trading.

Shares of Prometheus Biosciences are surging after the company announced positive results from its PRA023 drug candidate in recent clinical trials. PRA023 is a IgG1 humanized monoclonal antibody that has shown the ability to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). This could help provide potentially-substantial improvements for patients suffering from moderate-to-severe irritable bowel disease (IBD).

PRA023 recently underwent a successful ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a clinical studies, which puts the drug candidate on the path to becoming both the first-in-class and the best-in-class treatment for Anti-TL1a mAb.

The Phase 2 ARTEMIS-UC trial was a 12-week, double-blind, placebo-controlled, randomized study that sought to test the efficacy and safety of PRA023 in patients suffering from moderate-to-severe active UC and have no responded to traditional treatments. The results showed 26.5% of patients being treated with PRA023 reached the primary endpoint of clinical remission, compared to only 1.5% in the placebo group. Furthermore, 36.8% of PRA023 patients achieved their secondary endpoint of endoscopic improvements, compared to only 6% in the placebo group.

During the Phase 2a APOLLO-CD trial, patients underwent a 12-week open-label study that enrolled 55 patients with moderate-to-severe active CD and have not responded to traditional treatments. The results showed 26% of patients on PRA023 saw a meaningful endoscopic response, compared to only 12% in the placebo group. In addition, 49.1% of patients taking the drug candidate achieved clinical remission compared to only 16% in the placebo group.

“PRA023 has clearly demonstrated clinical proof-of-concept in CD and remarkable efficacy for the treatment of UC,” added Allison Luo, MD, Chief Medical Officer. “We are grateful to all of our investigators and patients for their participation and look forward to further evaluating PRA023 in Phase 3 studies with the goal of bringing this promising candidate to the market.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Prometheus Biosciences (NASDAQ: RXDX) Reports PRA023 Candidate Achieved Positive Results in Both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Clinical Trials appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.